This is the case for TP53 Y220C mutation, which is present in up to 2.9% of STS and 1.2% of bone sarcomas (rhabdomyosarcoma, leiomyosarcoma, sarcoma NOS, and osteosarcoma). This evidence concerns the gene TP53 and leiomyosarcoma.